Loading…
Loading…
CRDL does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CRDL and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CRDL and 80,000+ other tickers.
See exactly how CRDL's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CRDL and 80,000+ other tickers.
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the…
Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management describing the program as a key step toward a potential new drug application.
Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) is expected to post its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors can check the company's upcoming Q2 2026 earning report page for the latest details on the call
TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on August 11, 2026, at 9:00 a.m. EDT. Canaccord Genuity's 46th Annual Growth Conference When: Tuesday, August 11 at 9:00 a.m.